Ruta de navegación

reuniones_cientificas_IV Symposium_banner

IV Symposium of Tropical Health

4 and 5 May 2017

IV Symposium of Tropical Health/COST Action CM 1307 (WG3 and WG4) Joint Meeting “Priorities in Tropical Health and parasite-borne disease: new drugs with new targets, and how to deliver them”

Aplicaciones anidadas

reuniones_cientificas_IV Symposium_txt_intro

Welcome

On behalf of the Organizing Committee, it is our great pleasure to invite you to the IV Symposium of Tropical Health/COST Action CM 1307 (WG3 and WG4) Joint Meeting “Priorities in Tropical Health and parasite-borne disease: new drugs with new targets, and how to deliver them”, which will be held on 4-5 May 2017 in Pamplona, Spain. The Symposium has been declared of sanitary interest by the Department of Health of the Government of Navarra.

Five plenary lectures will be presented and up to twenty talks from proffered abstracts will be selected and integrated into plenary sessions. In addition, one session of Poster Flash Presentations will take place.

Pamplona, the capital of Navarra, is a modern and welcoming city that invites you to its many pleasures: enjoy its parks, stroll through the streets of its Old Quarter, walk around century-old walls and rest on its scenic terraces. Discover all of these particularities of Pamplona and do not forget to taste its gastronomy and its popular tapas (or pinchos as they are known locally).

We are looking forward to seeing you enjoying the Symposium and all that Pamplona has to offer.

Aplicaciones anidadas

reuniones_cientificas_IV Symposium_tit_program

Program

Aplicaciones anidadas

reuniones_cientificas_IV Symposium_day1

MAY 4TH

9:00 Registration

9:15 Welcome and Opening Remarks

A.MEDICINAL CHEMISTRY

Chairpersons: Philippe M. Loiseau and Thomas J. Schmidt

9:30-10:15 Plenary Lecture A: New drugs against Onchocerca filarial parasites: Lessons from the bovine model in Cameroon. Alfons Renz. University of Tübingen, Germany

10:15-10:45 Coffee break-Poster viewing

10:45- 11:45 Oral communications (OC), 15+5 min/ communication

  • OC 1A:Looking for hits and leads through library screening in the NMTRYPI platform in the field of trypanosomatidic infections. Maria Paola Costi, Università Degli Studi di Modena e Reggio Emilia
  • OC 2A: Antileishmanial activity of methylselenocarbamates. Mikel Etxebeste. Instituto de Salud Tropical University of Navarra (ISTUN), Spain
  • OC 3A:Generating evidence for a single drug combination dose (ivermectin+albendazole) to improve mass drug administration programmes to control soil transmitedhelmints, strongyloidesstercoralis included, in Bahir Dar, Amhara region, Ethiopia.Juan José de los Santos Sanz-Bustillo. Mundo Sano Foundation

11:45-12:45 Poster Flash Presentation (PF), 4+1 min/ poster

  • PF 1 On the road to functional understanding the divergent actin 2, a new target for malaria transmission blocking. Maria Andreadaki, Institute of Molecular Biology and Biotechnology, FORTH, Heraklion, Greece
  • PF 2: Leishmania major nucleus–located Yinp protein is a genotoxic drugs target. Miriam Algarabel. Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Microbiología y Parasitología, Spain
  • PF 3: Involvement of the serine/threonine kinase – Jean3 – in leishmania infectivity. Celia Fernández Rubio, Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Microbiología y Parasitología, Spain
  • PF 4: Lactococcus lactis HSP65 producer as an alternative therapy for cutaneous leishmaniasis. Juliana Rebouças, Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
  • PF 5: Leishmania vaccination using microneedles and nucleosomal histones. Esther Moreno, Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Farmacia y Tecnología Farmacéutica, Spain
  • PF 6: Histone fold domain dimerization of oocyst rupture proteins (ORPs) as target for antimalarial drugs development. Chiara Currà, Institute of Molecular Biology and Biotechnology, FORTH, Heraklion, Greece
  • PF 7: Study and characterization of a newly discovered oncogenic domain in leishmaniaspp. José Peña, Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Microbiología y Parasitología, Spain
  • PF 8: Exploring the scope of new arylamino alcohol derivatives: synthesis, antimalarial evaluation, toxicological studies, and target exploration. Miguel Quiliano, Instituto de Salud Tropical (ISTUN), Departamento de Química Orgánica y Farmacéutica, Spain
  • PF 9: Angiostrongylus cantonensis. Emergencia en América. Alberto Juan Dorta-Contreras. Laboratorio Central de Líquido Cefalorraquídeo (LABCEL). Facultad de Ciencias Médicas “Miguel Enríquez”, Universidad de Ciencias Médicas de La Habana, Cuba.

12:45-13:45 Lunch

B.NATURAL PRODUCTS AS ANTIPARASITIC AGENTS

Chairpersons: Harry P. de Koning and Alfons Renz

13:45-14:30 Plenary Lecture B:Antischistosomal and mosquitocidal secondary metabolites from medicinal African plants. JosphatMatasyoh, University of Egerton, Kenya

14:30-15:50 Oral communications

  • OC 1B: Drug targeting of natural products: the example of antileishmanial quinolines. Philippe M. Loiseau. Université Paris-Sud, France
  • OC 2B: Steroidal alkaloids with anti-trypanosomal activity from Holarrhena africana (Apocynaceae). Thomas J. Schmidt. Institute of Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, Germany
  • OC 3B: Natural products are closer to drugs than non-drugs and can find use in antiparasitic treatment. Alfonso T. García-Sosa. Institute of Chemistry, University of Tartu, Estonia
  • OC 4B: Anti-trypanosomalelemanolide sesquiterpene lactones from Vernonialasiopus O. Hoffm. Mark Kimani. Institute of Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, Germany

15:50-16:35 Plenary Lecture B: Antileishmanial lead-finding from Plantæ columbianæ: pursuit of proof-of-concepts using modern approaches.Ericsson Coy Nueva Granada Military University. Department of Chemistry. Bogotá, Colombia.

16:35-16:45 Coffee break-Poster viewing

16:45 – 17:15 Working session

17:30 Guided Tour

20.30 Dinner at Café Iruña

reuniones_cientificas_IV Symposium_day2

MAY 5TH

C.BIOLOGICAL TARGETS FOR CHEMOTHERAPY

Chairpersons: Juan M. Irache and JosphatMatasyoh

9:00-9:45 Plenary Lecture C: Development of nanocarriers for innovative antimalarial combination strategies. Xavier Fernández-Busquets, Institute for Global Health (ISGlobal). University of Barcelona, Spain

9:45-11:05 Oral communications

  • OC 1C: Transmission blocking targets in Plasmodium berghei mosquito midgut stages. Inga Siden-Kiamos. Foundation for Research and Technology-Hellas, Institute of Molecular Biology and Biotechnology, Heraklion, Greece.
  • OC 2C: Strategies to identify the genes encoding pyrimidine-specific transporters in protozoa. Khalid Jamaan Alzahrani. Institute of Infection, Immunity and Inflammation, University of Glasgow, United Kingdom; Department of Clinical Laboratory, College of Applied Medical Sciences, Taif University, Saudi Arabia.
  • OC 3C: Trypanothione reductase and superoxide dismutase as current drug targets for Trypanosoma cruzi: an overview of compounds with activity against Chagas disease. Iván Beltrán-Hortelano. Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departamento de Química Orgánica y Farmacéutica, Spain.
  • OC 4C: Recent neuroimmunological findings in eosinophilic meningoencephalitis due to Angiostrongylus cantonensis.Alberto Juan Dorta-Contreras. Laboratorio Central de Líquido Cefalorraquídeo (LABCEL). Facultad de Ciencias Médicas “Miguel Enríquez”, Universidad de Ciencias Médicas de La Habana, Cuba.

11:05-11:30 Coffee break-Poster viewing

D.DRUG TARGETING AND DRUG RESISTANCE

Chairpersons: Francisco J. Otero Espinar andAlfonso T. García-Sosa

11:30-12:15 Plenary Lecture D: A cell targeting nanostrategy to bypass drug resistances in African trypanosomiasis. José Luis Arias Mediano. University of Granada, Spain

12:15-13:00 Oral communications

  • OC 1D: A decrease in mitochondrial membrane potential is associated with diminazene resistance in Trypanosoma congolense. Harry P. de Koning. Institute of Infection, Immunity and Inflammation, University of Glasgow, United Kingdom.
  • OC 2D: An ex vivo phenotypic screening for antileishmanial drugs using infrared-transgenic cells.Rosa Mª Reguera. Dpt. Biomedical Sciences; University of León, Spain

13:00-14:30 Lunch-Poster viewing

Chairpersons: Socorro Espuelas and Fabio Rocha Formiga

14:30-15:30 Oral Communications

  • OC 3D: Developing nanoparticles for 17-AAGdelivery against Leishmania infection. Fabio Rocha Formiga.GonçaloMonizInstitute, Oswaldo Cruz Foundation (FIOCRUZ/BA), Salvador, Brazil
  • OC 4D: Lipid-based EmulsomeNanoformulations for Targeted Delivery of Antiparasites. Mehmet HikmetUcisik. Department of Biomedical Engineering, School of Engineering and Natural Sciences, Istanbul Medipol University; Medipol Regenerative and Restorative Medicine Research Center (REMER), Istanbul, Turkey.
  • OC 5D: The trypanosomatid serine/threonine protein kinase “Jean3” may confer resistance to drugs such as paromomycin.Andrés Vacas-Oleas. Instituto de Salud Tropical University of Navarra (ISTUN), Spain

15:30-16:15 Plenary lecture E: The quest for new vaccines against brucellosis. Ignacio Moriyón. Universidad de Navarra, Instituto de Salud Tropical (ISTUN), Departmentof Microbiology and Parasitology, Spain.

16:15–18:00 Meeting of the Working Groups 3 and 4

Aplicaciones anidadas

reuniones_cientificas_IV Symposium_tit_ Comittee

Comittee

Aplicaciones anidadas

reuniones_cientificas_IV Symposium_organizadores1

Organizers

  • Dr. Paul Nguewa

  • Dra. Socorro Espuelas

  • Dra. Carmen Sanmartin

  • Dra. Silvia Pérez Silanes

  • Dra. Silvia Galiano

  • Dr. Ignacio Moriyón

  • Dr. Carlos Gamazo

  • Dra. Silvia Carlos

  • Dr. Gabriel Reina

  • Dra. Esther Larrea

  • Dr. Philippe Loiseau

  • Dr. Juan Manuel Irache

 

Scientific Comittee

  • Dr. Philippe Loiseau

  • Dra. Ana Tomas

  • Dr. Francisco J. Otero Espinar

  • Dra. Socorro Espuelas

  • Dr. Vassilios Roussis

  • Dr. Thomas J. Schmidt

  • Dr. Harry P. de Koning

  • Dr. Basilio Valladares

  • Dr. Juan Manuel Irache

  • Dr. Paul Nguewa

reuniones_cientificas_IV Symposium_organizadores2

Honor Comitte

  • Uxue Barkos
    President of the Government of Navarra

  • Joseba Asirón
    Mayor of Pamplona

  • Fernando Domínguez Cunchillos
    Councilor of Health for the Government of Navarra

  • Alfonso Sánchez-Tabernero
    President of the University of Navarra

  • María Pilar Civeira
    Director of the Center for Applied Medical Research

  • Iciar Astiasarán
    Vice-President for Research. University of Navarra

  • Luis Montuenga
    Dean of the School of Sciences. University of Navarra

  • Secundino Fernández
    Dean of the School of Medicine. University of Navarra

  • Mercedes Pérez Diez del Corral
    Dean of the School of Nursing. University of Navarra

  • Adela López de Cerain
    Dean of the School of Pharmacy. University of Navarra

 

 

Technical comittee

  • Susana Murillo

  • María Orbe

  • María Asunción Labarta

  • Guillermo Sainz

  • Patricia Sainz de Robredo

  • Raquel Arilla